Cargando…

Tissue-Type Plasminogen Activator and Tenecteplase-Mediated Increase in Blood Brain Barrier Permeability Involves Cell Intrinsic Complement

Background: Tissue-type plasminogen activator (t-PA) has been the mainstay of therapeutic thrombolysis for patients with acute ischaemic stroke (AIS). However, t-PA can cause devastating intracerebral hemorrhage. t-PA can also influence the CNS in part by modulation of BBB permeability. Complement a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Keragala, Charithani B., Woodruff, Trent M., Liu, Zikou, Niego, Be'eri, Ho, Heidi, McQuilten, Zoe, Medcalf, Robert L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753024/ https://www.ncbi.nlm.nih.gov/pubmed/33363504 http://dx.doi.org/10.3389/fneur.2020.577272

Ejemplares similares

t-PA Suppresses the Immune Response and Aggravates Neurological Deficit in a Murine Model of Ischemic Stroke
por: Draxler, Dominik F., et al.
Publicado: (2019)

A novel ex vivo approach for measuring plasminogen activation upon established plasma clots
por: Palazzolo, Jason S., et al.
Publicado: (2022)

LDL receptor blockade reduces mortality in a mouse model of ischaemic stroke without improving tissue-type plasminogen activator-induced brain haemorrhage: towards pre-clinical simulation of symptomatic ICH
por: Niego, Be’eri, et al.
Publicado: (2017)

Fibrinolysis: A Primordial System Linked to the Immune Response
por: Medcalf, Robert L., et al.
Publicado: (2021)

The Fibrinolytic System: Mysteries and Opportunities
por: Medcalf, Robert L., et al.
Publicado: (2021)

Plasmin Generation Potential and Recanalization in Acute Ischaemic Stroke; an Observational Cohort Study of Stroke Biobank Samples
por: Lillicrap, Thomas, et al.
Publicado: (2020)

Selective inhibition of brain endothelial Rho-kinase-2 provides optimal protection of an in vitro blood-brain barrier from tissue-type plasminogen activator and plasmin
por: Niego, Be’eri, et al.
Publicado: (2017)

Tenecteplase Thrombolysis in Posterior Circulation Stroke
por: Alemseged, Fana, et al.
Publicado: (2021)

Tranexamic acid in a mouse model of cerebral amyloid angiopathy: setting the stage for a novel stroke treatment approach
por: Liu, Zikou, et al.
Publicado: (2023)

The Influence of Differentially Expressed Tissue-Type Plasminogen Activator in Experimental Autoimmune Encephalomyelitis: Implications for Multiple Sclerosis
por: Dahl, Lisa CM, et al.
Publicado: (2016)

Tranexamic acid alters the immunophenotype of phagocytes after lower limb surgery
por: Draxler, Dominik F., et al.
Publicado: (2022)

Tranexamic acid for haemostasis and beyond: does dose matter?
por: Lam, Tammy, et al.
Publicado: (2023)

A Comparative Study of Hemorrhagic Conversion Patterns After Stroke Thrombolysis With Alteplase Versus Tenecteplase
por: Ezzeldin, Mohamad, et al.
Publicado: (2023)

Tenecteplase vs. alteplase for treatment of acute ischemic stroke: A systematic review and meta-analysis of randomized trials
por: Kobeissi, Hassan, et al.
Publicado: (2023)

Anticoagulation in COVID-19
por: Bradbury, Charlotte A, et al.
Publicado: (2022)

Intra-arterial tenecteplase is safe and may improve the first-pass recanalization for acute ischemic stroke with large-artery atherosclerosis: the BRETIS-TNK trial
por: Zhao, Zi-Ai, et al.
Publicado: (2023)

Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance (Mobile Stroke Unit—TASTE-A): protocol for a prospective randomised, open-label, blinded endpoint, phase II superiority trial of tenecteplase versus alteplase for ischaemic stroke patients presenting within 4.5 hours of symptom onset to the mobile stroke unit
por: Bivard, Andrew, et al.
Publicado: (2022)

Trail Toward Tenecteplase
por: Srivastava, Trilochan, et al.
Publicado: (2022)

Shear-Dependent Platelet Aggregation: Mechanisms and Therapeutic Opportunities
por: Rana, Akshita, et al.
Publicado: (2019)

Platelet-targeted thrombolysis for treatment of acute ischemic stroke
por: Palazzolo, Jason S., et al.
Publicado: (2022)

Different doses of tenecteplase vs. alteplase for acute ischemic stroke within 4.5 hours of symptom onset: a network meta-analysis of randomized controlled trials
por: Liang, Huo, et al.
Publicado: (2023)

Expanding Footprints of Biosimilar Tenecteplase
por: Subhash, et al.
Publicado: (2023)

How should we use convalescent plasma therapies for the management of COVID-19?
por: Wood, Erica M., et al.
Publicado: (2021)

Assessment of the epi-pericardial fibrotic substrate by collagen-targeted probes
por: Ezeani, Martin, et al.
Publicado: (2022)

Management of Pediatric Strokes With Alteplase (Tissue Plasminogen Activator)
por: Filatov, Asia, et al.
Publicado: (2021)

Platelet storage duration and its clinical and transfusion outcomes: a systematic review
por: Aubron, Cécile, et al.
Publicado: (2018)

Intracoronary tenecteplase in STEMI with massive thrombus
por: Jayagopal, P.B., et al.
Publicado: (2018)

Tenecteplase: Haemorrhagic pericarditis: case report
Publicado: (2020)

Tenecteplase in Ischemic Stroke: Challenge and Opportunity
por: Li, Guangshuo, et al.
Publicado: (2022)

Replacing Alteplase with Tenecteplase: Is the Time Ripe?
por: Singh, Nishita, et al.
Publicado: (2023)

The Norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke
por: Logallo, Nicola, et al.
Publicado: (2014)

Tissue plasminogen activator and patients with acute ischemic stroke: The litigation landscape
por: Ganti, Latha, et al.
Publicado: (2022)

Quantitative Imaging of Blood-Brain Barrier Permeability Following Repetitive Mild Head Impacts
por: Leaston, Joshua, et al.
Publicado: (2021)

A Description of the Type, Frequency and Severity of Infections Among Sixteen Patients Treated for T-Cell Lymphoma
por: Ko, Tina, et al.
Publicado: (2021)

Intrapleural Tenecteplase for Complicated Parapneumonic Pleural Effusion
por: Kadhem, Husain, et al.
Publicado: (2021)

Tenecteplase or Alteplase: What Is the Thrombolytic Agent of the Future?
por: Mahmood, Ammad, et al.
Publicado: (2022)

Novel Thrombolytic Drug Based on Thrombin Cleavable Microplasminogen Coupled to a Single‐Chain Antibody Specific for Activated GPIIb/IIIa
por: Bonnard, Thomas, et al.
Publicado: (2017)

The Peripheral Immune System and Amyotrophic Lateral Sclerosis
por: McCombe, Pamela A., et al.
Publicado: (2020)

Collagen‐Targeted Peptides for Molecular Imaging of Diffuse Cardiac Fibrosis
por: Ezeani, Martin, et al.
Publicado: (2021)

Peripheral Blood and Salivary Biomarkers of Blood–Brain Barrier Permeability and Neuronal Damage: Clinical and Applied Concepts
por: Janigro, Damir, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7qjji4kpf4qk71u5ku37l391qm